睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06646211,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically documented PCNSL

    入选标准第 2 条

  3. Known history of infection with human immunodeficiency virus (HIV) or active stage of infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) . Active HBV infection must be confirmed by a positive test for HBV surface antigen or a positive test for hepatitis B core antibody with a positive determination of HBV DNA by polymerase chain reaction (PCR). For Hepatitis C virus (HCV), confirmation must be made by a positive test for HCV antibodies, unless the subject has been treated and has shown a sustained virological response. Note: Subjects with positive HCV antibodies who have been treated and have shown a sustained virological response (negative virus detection for at least 6 months after completing treatment) will not be excluded.

    排除标准第 12 条

  4. Received curative treatment and has no known active disease at least 3 years or more before screening for enrollment.

    排除标准第 2 条

    Patient underwent major systemic surgery ≤ 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery

    排除标准第 13 条

  5. ECOG performance status ≤ 2

    入选标准第 3 条

  6. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L

    入选标准第 7 条

    Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days

    入选标准第 8 条

    Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days

    入选标准第 9 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN

    入选标准第 11 条

    Serum bilirubin ≤ 1.5×ULN

    入选标准第 12 条

    Serum creatinine ≤ 2×ULN

    入选标准第 13 条

  7. Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of medication; women who are pregnant or breastfeeding are not eligible to participate in this study. Women of childbearing potential: from the time of signing the Informed Consent Form (ICF) until 30 days after the study ends, sexually active men: from the time of signing the ICF until 90 days after the study ends, must use contraceptive measures.

    入选标准第 15 条

    Lactating or pregnant

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06646211,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Men and woman who are 18 to 70 years of age
  2. Histologically documented PCNSL
  3. ECOG performance status ≤ 2
  4. Life expectancy of > 3 months
  5. Imaging show at least one measurable lesion in the central nervous system.
  6. Adequate bone marrow and organ function shown by:
  7. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
  8. Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days
  9. Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days
  10. International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal
  11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN
  12. Serum bilirubin ≤ 1.5×ULN
  13. Serum creatinine ≤ 2×ULN
  14. Lipase ≤ 1.5 x LUN
  15. Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of medication; women who are pregnant or breastfeeding are not eligible to participate in this study. Women of childbearing potential: from the time of signing the Informed Consent Form (ICF) until 30 days after the study ends, sexually active men: from the time of signing the ICF until 90 days after the study ends, must use contraceptive measures.
  16. Must be able to tolerate MRI/CT scans
  17. Must be able to tolerate lumbar puncture and/or Ommaya tap

排除标准:Exclusion Criteria:

  1. Diagnosed with a malignant tumor other than PCNSL or has received treatment, except for the following cases:
  2. Received curative treatment and has no known active disease at least 3 years or more before screening for enrollment.
  3. Fully treated non-melanoma skin cancer or malignant lentigo, with no evidence of disease.
  4. Fully treated carcinoma in situ, with no evidence of disease currently.
  5. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association > Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
  6. Uncontrolled hypertension despite optimal medical management (per investigators assessment)
  7. Patient has poorly controlled diabetes (per investigators assessment)
  8. Patient is known to have an uncontrolled active systemic infection (>CTCAE grade 2) and recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug
  9. Cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment
  10. Non-healing wound, ulcer or bone fracture in a short time
  11. Known bleeding diathesis or hemophilia
  12. Known history of infection with human immunodeficiency virus (HIV) or active stage of infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) . Active HBV infection must be confirmed by a positive test for HBV surface antigen or a positive test for hepatitis B core antibody with a positive determination of HBV DNA by polymerase chain reaction (PCR). For Hepatitis C virus (HCV), confirmation must be made by a positive test for HCV antibodies, unless the subject has been treated and has shown a sustained virological response. Note: Subjects with positive HCV antibodies who have been treated and have shown a sustained virological response (negative virus detection for at least 6 months after completing treatment) will not be excluded.
  13. Patient underwent major systemic surgery ≤ 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery
  14. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  15. Life-threatening illness, medical conditions, or organ dysfunctions that may endanger the safety of the subject or put the study outcomes at risk.
  16. Lactating or pregnant
  17. Requires anticoagulation therapy with warfarin or equivalent vitamin K antagonists; requires treatment with potent CYP3A4/5 inhibitors.
  18. Requires long-term use of dexamethasone ≥4mg/day or equivalent doses of corticosteroid formulations.
  19. Requires treatment with immunosuppressive agents, including cyclosporine A, tacrolimus, and sirolimus. Patients must discontinue the use of immunosuppressive agents 28 days before receiving study medication.

引自 ClinicalTrials.gov, NCT06646211, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06646211,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06646211